The impact of rifaximin on the NHS hospital resource use associated with the management of patients with hepatic encephalopathy (HE): a retrospective observational study

Trial Profile

The impact of rifaximin on the NHS hospital resource use associated with the management of patients with hepatic encephalopathy (HE): a retrospective observational study

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 May 2017

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Hepatic encephalopathy
  • Focus Therapeutic Use
  • Acronyms IMPRESS
  • Sponsors Norgine
  • Most Recent Events

    • 21 Apr 2017 According to a Norgine media release, data was presented at The International Liver Congress in April 2017.
    • 02 Nov 2016 Results assessing the impact of rifaximin-aplha on the costs associated with hospital admissions and attendances in patients with Hepatic-encephalopathy, presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 31 Oct 2016 Results published in Norgine media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top